Cardiac Failure in Very Long Chain Acyl-Coa Dehydrogenase Deficiency Requiring Extracorporeal Membrane Oxygenation (ECMO) Treatment: A Case Report and Review of the Literature

שרון כץ 1,6 Yuval E. Landau 2,6 Ben Pode-Shakked 2,3,6 Itai M. Pessach 3,4,6 Marina Rubinshtein 4 Yair Anikster 2,6 Yishay Salem 5,6 Gideon Paret 4,6
1Department of Pediatrics B, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel-Hashomer
2Metabolic Disease Unit, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel-Hashomer
3The Dr. Pinchas Borenstein Talpiot Medical Leadership Program, Sheba Medical Center, Tel-Hashomer
4Department of Pediatric Intensive Care, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel-Hashomer
5Pediatric Cardiology Unit, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel-Hashomer
6Sackler Faculty of Medicine, Tel-Aviv University

Fatty acid oxidation (FAO) defects often present with multi-system involvement, including several life-threatening cardiac manifestations, such as cardiomyopathy, pericardial effusion and arrhythmias.

We report herein a fatal case of cardiac dysfunction and rapid-onset tamponade following an acute illness in a neonate with molecularly proven very long chain acyl-CoA dehydrogenase (VLCAD) deficiency, requiring 15 days of extracorporeal membrane oxygenation (ECMO) treatment.

As data regarding the use of ECMO in FAO defects in general, and VLCAD deficiency in particular, are scarce, we review the literature and discuss insights from in vitro models and several successful reported cases.

שרון כץ
שרון כץ
Hadassah medical center








Powered by Eventact EMS